REGISTER
World’s First! Chinese Doctors Successfully Treat Lupus with In Vivo CAR-T Therapy

A team of Chinese scientists has achieved another breakthrough in the treatment of Systemic Lupus Erythematosus (SLE).

On September 18, a landmark paper published in the New England Journal of Medicine reported that Chinese physicians successfully treated five patients with refractory SLE using in vivo CAR-T cell therapy—marking the world’s first application of this technology in a human study for autoimmune disease.

The study was conducted through collaboration among Dr. Zhu Chen, Chief of Rheumatology and Immunology at the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Dr. Georg Schett, University Hospital Erlangen, and a domestic biotech company.

“The patients are recovering remarkably well, with significant improvements in SLE disease activity scores and symptoms,” Dr. Chen told MedJ.

As a disruptive advancement in CAR-T therapy, in vivo CAR-T technology addresses key limitations of conventional CAR-T approaches and is expected to reduce treatment costs—currently as high as one million RMB per dose—by tens to hundreds of times.

“This represents an exploration into a new treatment paradigm. We will further advance this research to provide low-cost, low-risk, and highly effective therapies for more patients with refractory SLE,” said Dr. Chen.

An Autoimmune Disease Affecting Millions

Systemic lupus erythematosus (SLE) is an autoimmune condition affecting millions worldwide. It causes severe damage to the brain, lungs, kidneys, and blood system. Even during non-acute phases, patients often suffer from fatigue, rashes, fever, and chronic pain.

Unfortunately, no cure currently exists for SLE. Treatment mainly relies on long-term use of corticosteroids, immunosuppressants, or biologics to control symptoms and maintain remission.

However, prolonged use of these drugs leads to significant side effects. Moreover, “some patients continue to experience cycles of relapse and remission or persistent disease activity despite trying all available treatments, severely impacting their quality of life. They urgently need new therapeutic options,” Dr. Chen explained.

CAR-T technology—including autologous, allogeneic, and the in vivo CAR-T used in this study—is considered one of the most promising frontier therapies for SLE.

The core mechanism of SLE involves immune dysregulation where B cells produce autoantibodies that attack the body’s own tissues. By engineering CD8+ T cells to recognize and eliminate these abnormal B cells, CAR-T therapy promotes immune reset and recovery.

Dr. Chen told MedJ that among the five patients treated, the longest disease course was 18 years. All had severe refractory SLE unresponsive to conventional therapies, and four had developed lupus nephritis.

According to the NEJM paper, CD8+ CD19-CAR T cells peaked in peripheral blood only six hours after in vivo CAR-T injection.
B cell depletion was observed within hours: patients receiving a 2mg dose showed significant B cell reduction, while those receiving 4mg achieved complete B cell clearance, sustained for 7–10 days.

“We found that CD8+ T cells were efficiently engineered into CD19-targeting CAR-T cells within hours—faster than we expected,” said Dr. Chen. “The modified cells began working immediately, reducing pathogenic B cells by nearly 90% in the low-dose group and nearly completely in the high-dose group.”

The longest-followed patient has now been monitored for over six months, with a substantial reduction in steroid dosage.
Another patient, who had severe vasculitis and neurological involvement with frequent intense headaches, has been symptom-free for four months post-treatment. Her SLE disease activity score dropped from 22 to 2.

A New Weapon Against Lupus

Professor Georg Schett of University Hospital Erlangen-Nuremberg, a pioneer in CAR-T therapy for SLE and Dr. Chen’s PhD supervisor, is a corresponding author of the study.
In 2021, his team reported the first successful use of CAR-T in an SLE patient in the NEJM. By February 2024, eight treated patients had achieved immune reconstitution without relapse.

Since 2023, Dr. Chen’s team has conducted a series of studies applying CAR-T to autoimmune diseases. In January of this year, they reported in Cell Research the first use of fourth-generation autologous CAR-T in three patients with refractory rheumatoid arthritis.

The current in vivo CAR-T project began preparation in June 2023. “Based on promising animal data, we obtained ethical approval and initiated the clinical study in February this year,” Dr. Chen said.

While autologous and allogeneic CAR-T have shown efficacy in SLE, both face challenges: autologous CAR-T is costly and time-consuming to produce, while allogeneic CAR-T carries risks of rejection and graft-versus-host disease. Both require lymphodepleting chemotherapy before infusion.

In vivo CAR-T addresses these issues by directly engineering T cells inside the patient using gene delivery vectors, avoiding the need for cell extraction, external manufacturing, or lymphodepletion.
“This could reduce costs by tens to hundreds of times and eliminates chemotherapy-related risks,” Dr. Chen noted.

A major challenge for in vivo CAR-T is targeting specificity. Dr. Chen stated that their technology showed excellent precision, with off-target CAR expression in non-CD8+ T cells below 10%.

Treatment was well-tolerated with no high-grade cytokine release syndrome, neurotoxicity, or significant organ toxicity observed.

The Best Opportunity to Conquer Autoimmune Diseases

The five patients will continue to be closely monitored in the coming months.
If results remain positive, Dr. Chen’s team plans to enroll more patients, optimize dosing—including exploring repeated administration—and advance toward investigational new drug (IND) trials.

The paper concludes that the data support the potential of in vivo CAR-T in autoimmune diseases, though larger studies are needed to assess long-term efficacy and ideal dosing.

There is still no unified definition of “cure” for SLE. Even after clinical remission, questions about durability and long-term safety require further study.
“Autologous CAR-T may offer stronger and more durable responses, while in vivo CAR-T is more accessible and safer. We need more research to understand the upper limits of each approach and how to tailor therapy based on disease stage,” Dr. Chen reflected.

Nevertheless, this may be one of the best opportunities yet to conquer SLE and other autoimmune diseases.
Nearly 20% of the global population is affected by over 100 different autoimmune conditions. CAR-T therapy has already shown encouraging results in SLE, systemic sclerosis, myositis, neuromyelitis optica, and others.

In early 2023, a major multinational pharmaceutical company stated that exploring CAR-T for autoimmune diseases had become a top priority, even surpassing cancer research.

Dr. Chen emphasized that cell therapies like CAR-T represent a paradigm shift from traditional antibody-based treatments.
“Previously, cell therapy was seen as a high-end, costly option for a limited few. With in vivo CAR-T, we can greatly improve accessibility—this is where the value of medical research truly lies.”

Reference:


  • 世界首次!安徽省立医院体内CAR T成功治疗狼疮 | NEJM https://mp.weixin.qq.com/s/OOTrFDjF8wilIq4LgzPuUQ



0
0
Loading